Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects
about
sameAs
Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humansClinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?
P2860
Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacodynamic characterizati ...... ht heparin in healthy subjects
@ast
Pharmacodynamic characterizati ...... ht heparin in healthy subjects
@en
Pharmacodynamic characterizati ...... ht heparin in healthy subjects
@nl
type
label
Pharmacodynamic characterizati ...... ht heparin in healthy subjects
@ast
Pharmacodynamic characterizati ...... ht heparin in healthy subjects
@en
Pharmacodynamic characterizati ...... ht heparin in healthy subjects
@nl
prefLabel
Pharmacodynamic characterizati ...... ht heparin in healthy subjects
@ast
Pharmacodynamic characterizati ...... ht heparin in healthy subjects
@en
Pharmacodynamic characterizati ...... ht heparin in healthy subjects
@nl
P2093
P2860
P1476
Pharmacodynamic characterizati ...... ht heparin in healthy subjects
@en
P2093
C M Kirchmaier
H K Breddin
H U Esslinger
U Klinkhardt
P2860
P304
P356
10.1046/J.0306-5251.2001.01446.X
P407
P577
2001-09-01T00:00:00Z